Sucampo Pharmaceuticals, Inc. Sustainability Profile
Sucampo Pharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 1996, the company has made significant strides in developing innovative therapies, particularly in the areas of gastrointestinal and ophthalmic disorders. Sucampo is renowned for its flagship product, Amitiza (lubiprostone), which offers unique benefits for patients suffering from chronic constipation and irritable bowel syndrome. With a strong focus on research and development, Sucampo has established a solid market position, recognised for its commitment to improving patient outcomes through advanced pharmaceutical solutions. The company operates primarily in North America and has expanded its reach into international markets, further solidifying its reputation as a leader in specialty pharmaceuticals.
DitchCarbon Score
How does Sucampo Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sucampo Pharmaceuticals, Inc.'s score of 38 is higher than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sucampo Pharmaceuticals, Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years. The company is a current subsidiary of Mallinckrodt plc, which may influence its climate commitments and emissions reporting. As of now, Sucampo Pharmaceuticals has not established any documented reduction targets or initiatives related to carbon emissions. The absence of specific emissions data and reduction commitments suggests that the company may be in the early stages of developing a comprehensive climate strategy. Given its affiliation with Mallinckrodt plc, any potential climate initiatives or emissions data may be inherited from this parent organisation. However, no specific emissions figures or reduction targets have been cascaded from Mallinckrodt plc to Sucampo Pharmaceuticals at this time. In summary, Sucampo Pharmaceuticals, Inc. is currently lacking in detailed emissions data and formal climate commitments, reflecting a need for further development in its sustainability practices.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 80,126,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 82,349,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | 000,000,000 |
How Carbon Intensive is Sucampo Pharmaceuticals, Inc.'s Industry?
How Carbon Intensive is Sucampo Pharmaceuticals, Inc.'s Location?
Sucampo Pharmaceuticals, Inc.'s Scope 3 Categories Breakdown
Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 61% of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 75% of Scope 3 emissions.
Top Scope 3 Categories
Sucampo Pharmaceuticals, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Sucampo Pharmaceuticals, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
